SK14832002A3 - Kryštalické liečivo - Google Patents

Kryštalické liečivo Download PDF

Info

Publication number
SK14832002A3
SK14832002A3 SK1483-2002A SK14832002A SK14832002A3 SK 14832002 A3 SK14832002 A3 SK 14832002A3 SK 14832002 A SK14832002 A SK 14832002A SK 14832002 A3 SK14832002 A3 SK 14832002A3
Authority
SK
Slovakia
Prior art keywords
lopinavir
crystalline form
type
solid state
absorption band
Prior art date
Application number
SK1483-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Daniel A. Dickman
Sanjay Chemburkar
James J. Fort
Rodger F. Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK14832002(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of SK14832002A3 publication Critical patent/SK14832002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1483-2002A 2000-03-30 2001-03-21 Kryštalické liečivo SK14832002A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
SK14832002A3 true SK14832002A3 (sk) 2003-02-04

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1483-2002A SK14832002A3 (sk) 2000-03-30 2001-03-21 Kryštalické liečivo

Country Status (22)

Country Link
EP (1) EP1268442A2 (ko)
JP (1) JP2003529592A (ko)
KR (1) KR100773258B1 (ko)
CN (2) CN1330639C (ko)
AR (2) AR033360A1 (ko)
AU (3) AU2001250920B2 (ko)
BG (1) BG107165A (ko)
BR (1) BR0109433A (ko)
CA (1) CA2403635A1 (ko)
CZ (1) CZ20023529A3 (ko)
HU (1) HUP0302675A3 (ko)
IL (1) IL151551A0 (ko)
MX (1) MXPA02009559A (ko)
MY (1) MY128296A (ko)
NO (1) NO325005B1 (ko)
NZ (1) NZ521183A (ko)
PE (1) PE20011232A1 (ko)
PL (1) PL359727A1 (ko)
SA (2) SA06270303B1 (ko)
SK (1) SK14832002A3 (ko)
TW (1) TWI284640B (ko)
WO (1) WO2001074787A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2010089753A2 (en) * 2009-02-06 2010-08-12 Hetero Research Foundation Novel polymorphs of lopinavir
WO2011025849A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
JP2003529592A (ja) 2003-10-07
SA06270303B1 (ar) 2009-08-02
TWI284640B (en) 2007-08-01
HUP0302675A2 (hu) 2003-12-29
KR100773258B1 (ko) 2007-11-05
KR20030011807A (ko) 2003-02-11
WO2001074787A2 (en) 2001-10-11
NO20024679D0 (no) 2002-09-30
AU5092001A (en) 2001-10-15
NZ521183A (en) 2004-03-26
AU2001250920B2 (en) 2006-06-29
CN101066952A (zh) 2007-11-07
PL359727A1 (en) 2004-09-06
WO2001074787A3 (en) 2002-02-07
NO325005B1 (no) 2008-01-14
AU2006222711A1 (en) 2006-10-19
BR0109433A (pt) 2004-08-10
AR049560A2 (es) 2006-08-16
PE20011232A1 (es) 2001-12-08
MY128296A (en) 2007-01-31
AR033360A1 (es) 2003-12-17
CN1330639C (zh) 2007-08-08
HUP0302675A3 (en) 2004-03-29
CA2403635A1 (en) 2001-10-11
IL151551A0 (en) 2003-04-10
EP1268442A2 (en) 2003-01-02
MXPA02009559A (es) 2003-05-21
SA01220270B1 (ar) 2006-11-14
NO20024679L (no) 2002-09-30
CN1422259A (zh) 2003-06-04
BG107165A (bg) 2003-07-31
CZ20023529A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
US8058433B2 (en) Crystalline pharmaceutical
KR102445601B1 (ko) 엘로빅시바트의 결정수식
KR20190057066A (ko) 세니크리비록 메실레이트의 고체 형태 및 세니크리비록 메실레이트의 고체 형태의 제조 방법
TWI227713B (en) Crystalline polymorph form II of ritonavir and its preparation and application
SK14832002A3 (sk) Kryštalické liečivo
TW202417453A (zh) ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式
AU2001250920A1 (en) Crystalline pharmaceutical
JP2014514274A (ja) マキサカルシトールの多形およびマキサカルシトールの調製方法
CN102428098B (zh) {[(2s，5r，8s，11s)-5-苄基-11-(3-胍基-丙基)-8-异丙基-7-甲基-3，6，9，12，15-五氧代-1，4，7，10，13-五氮杂-环十五烷-2-基]-乙酸}的新固体物质和获得它们的方法
EA031174B1 (ru) Твёрдая форма тенофовира
EP2397473A1 (en) A stable highly crystalline anacetrapib
ZA200206962B (en) Crystalline pharmaceutical.
JPWO2003010152A1 (ja) アリールエテンスルホンアミド誘導体の新規結晶及びその製造法
WO2010131118A2 (en) Polymorphs of etravirine and processes for preparation thereof
US7612225B2 (en) Crystal of triterpene derivative
TW202334164A (zh) （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型
CN105612160A (zh) 用作半胱氨酸蛋白酶抑制剂的N-[1-6-(乙炔基-3-氧代-六氢-呋喃并[3,2-b]吡咯-4-羰基)-3-甲基-丁基]-4-[5-氟-2-(4-甲基-哌嗪基)噻唑-4-基]-苯甲酰胺的盐的形式2结晶多晶型物

Legal Events

Date Code Title Description
FC9A Refused patent application